$17.72
0.17% yesterday
Nasdaq, Sep 24, 10:00 pm CET
ISIN
CH1242303498
Symbol
OCS

Oculis Stock price

$17.72
-0.07 0.39% 1M
-1.89 9.64% 6M
+0.72 4.24% YTD
+5.61 46.33% 1Y
+7.81 78.81% 3Y
+8.03 82.87% 5Y
+8.03 82.87% 10Y
+8.03 82.87% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.03 0.17%
ISIN
CH1242303498
Symbol
OCS
Industry

Key metrics

Basic
Market capitalization
$966.3m
Enterprise Value
$892.4m
Net debt
positive
Cash
$75.3m
Shares outstanding
55.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 818.9
EV/Sales
- | 756.2
EV/FCF
negative
P/B
4.7
Financial Health
Equity Ratio
61.0%
Return on Equity
-116.9%
ROCE
-47.3%
ROIC
-62.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $1.2m
EBITDA
$-97.4m | $-106.3m
EBIT
$-97.9m | $-103.2m
Net Income
$-129.4m | $-132.3m
Free Cash Flow
$-68.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-52.0% | -16.1%
EBIT
-52.0% | -12.1%
Net Income
-74.7% | -22.6%
Free Cash Flow
18.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -9,011.9%
EBIT
-
Net
- | -11,207.8%
Free Cash Flow
-
More
EPS
$-2.7
FCF per Share
$-1.2
Short interest
0.0%
Employees
49
Rev per Employee
$0.0
Show more

Is Oculis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Oculis Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Oculis forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Oculis forecast:

Buy
92%
Hold
8%

Financial data from Oculis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 62 62
43% 43%
-
-62 -62
43% 43%
-
- Selling and Administrative Expenses 15 15
50% 50%
-
- Research and Development Expense 17 17
93% 93%
-
-97 -97
52% 52%
-
- Depreciation and Amortization 0.57 0.57
50% 50%
-
EBIT (Operating Income) EBIT -98 -98
52% 52%
-
Net Profit -129 -129
75% 75%
-

In millions USD.

Don't miss a Thing! We will send you all news about Oculis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Oculis Stock News

Neutral
GlobeNewsWire
3 days ago
ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial
Neutral
GlobeNewsWire
3 days ago
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial
Neutral
GlobeNewsWire
16 days ago
ZUG, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
More Oculis News

Company Profile

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Riad Sherif
Employees 49
Founded 2016
Website oculis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today